

Publications of the International Breast Cancer Study Group

IBCSG 36-07

431. de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman DW, Colleoni M, Roylance R, Kelly CM, Lombard J, El-Abed S, Choudhury A, Korde L, Vicente M, Chumsri S, Rodeheffer R, Ellard SL, Wolff AC, Holtschmidt J, Lang I, Untch M, Boyle F, Xu B, Werutsky G, Tujakowski J, Huang CS, Baruch NB, Bliss J, Ferro A, Gralow J, Kim SB, Kroep JR, Krop I, Kuemmel S, McConnell R, Moscetti L, Knop AS, van Duijnhoven F, Gomez H, Cameron D, Di Cosimo S, Gelber RD, Moreno-Aspitia A. Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]. *ESMO Open* 2024;9(11):103938. doi: 10.1016/j.esmoop.2024.103938. Epub 2024 Oct 16. (IBCSG 36-07) (Journal Impact Factor 7.1).

396. Moreno-Aspitia A, Holmes EM, Jackisch C, de Azambuja E, Boyle F, Hillman DW, Korde L, Fumagalli D, Izquierdo MA, McCullough AE, Wolff AC, Pritchard KI, Untch M, Guillaume S, Ewer MS, Shao Z, Sim SH, Aziz Z, Demetriou G, Mehta AO, Andersson M, Toi M, Lang I, Xu B, Smith IE, Barrios CH, Baselga J, Gelber RD, Piccart-Gebhart M, for the ALTTO Steering Committee and Investigators. Updated results from the International Phase III ALTTO Trial (BIG 2-06/Alliance N063D): Presented at the 2017 Annual Meeting of the American Society of Clinical Oncology. *Eur J Cancer* 2021;148:287-296. doi: 10.1016/j.ejca.2021.01.053. Epub 2021 March 22. (IBCSG 36-07) (Journal Impact Factor 7.275).

376. Holmes EM, Bradbury I, Williams LS, Korde L, de Azambuja E, Fumagalli D, Moreno-Aspitia A, Baselga J, Piccart-Gebhart M, Dueck AC, Gelber RD. Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial. *Ann Oncol*. doi: 10.1093/annonc/mdz195. 2019 June 26. [Epub ahead of print] (IBCSG 36-07) (Journal Impact Factor 13.926).

325. Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im, JH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results from the randomized phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial. *J Clin Oncol* 34:1034–1042, 2016. (IBCSG 36-07) (Journal impact factor 18.443).

300. McCullough AE, Dell'Orto P, Reinholz MM, Gelber RD, Dueck AC, Russo L, Jenkins RB, Andrighetto S, Chen B, Jackisch C, Untch M, Perez EA, Piccart-Gebhart MJ, Viale G. Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study. *Breast Cancer Res Treat* 143:485-492, 2014. (IBCSG 36-07) (Journal impact factor 4.469).